Research progress on rat model of drug-induced liver injury established by nonsteroidal anti-inflammatory drug (celecoxib) and royal jelly ameliorative effect.
J Complement Integr Med
; 21(2): 239-247, 2024 Jun 01.
Article
em En
| MEDLINE
| ID: mdl-38281144
ABSTRACT
OBJECTIVES:
NSAIDs, like celecoxib, are widely used to treat pain, fever, and inflammation, with celecoxib being particularly effective in managing arthritis symptoms and acute or chronic pain especially with its favorable gastrointestinal tolerability. The study aimed at exploring the effect of chronic administration of celecoxib on hepatic tissues in male albino rats. It also examined the royal jelly celecoxib interplay.METHODS:
50 male albino rats in 5 equal groups; Group 1 received no drug. Group 2 received celecoxib (50 mg/kg/day, orally), for 30 successive days. Group 3 received celecoxib plus royal jelly (300 mg/kg/day, orally) for 30 successive days. Group 4 received celecoxib, for 30 days, then were left untreated for another 30 days. Group 5 received celecoxib plus royal jelly for 30 days, then were left untreated for another 30 days.RESULTS:
Chronic celecoxib administration caused hepatotoxicity in male albino rats, with ameliorative effect of royal jelly. Celecoxib discontinuation significantly diminished the celecoxib-induced toxicity, and normal liver enzymes and serum protein levels were regained in the case of dual medications (celecoxib+RJ) discontinuation.CONCLUSIONS:
Long-term celecoxib administration caused hepatotoxicity, with ameliorative effects of royal jelly against celecoxib-induced oxidative and apoptotic stress. In addition, it could be concluded that royal jelly may prove a useful adjunct in patients being prescribed celecoxib.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Anti-Inflamatórios não Esteroides
/
Ácidos Graxos
/
Doença Hepática Induzida por Substâncias e Drogas
/
Celecoxib
/
Fígado
Limite:
Animals
Idioma:
En
Revista:
J Complement Integr Med
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Egito